Literature DB >> 33604794

Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors.

Mangala Hegde1, Manjunath B Joshi2.   

Abstract

Significant reprogramming of epigenome is widely described during pathogenesis of breast cancer. Transformation of normal cell to hyperplastic cell and to neoplastic phenotype is associated with aberrant DNA (de)methylation, which, through promoter and enhancer methylation changes, activates oncogenes and silence tumor suppressor genes in variety of tumors including breast. DNA methylation, one of the major epigenetic mechanisms is catalyzed by evolutionarily conserved isoforms namely, DNMT1, DNMT3A and DNMT3B in humans. Over the years, studies have demonstrated intricate and complex regulation of DNMT isoforms at transcriptional, translational and post-translational levels. The recent findings of allosteric regulation of DNMT isoforms and regulation by other interacting chromatin modifying proteins emphasizes functional integrity and their contribution for the development of breast cancer and progression. DNMT isoforms are regulated by several intrinsic and extrinsic parameters. In the present review, we have extensively performed bioinformatics analysis of expression of DNMT isoforms along with their transcriptional and post-transcriptional regulators such as transcription factors, interacting proteins, hormones, cytokines and dietary elements along with their significance during pathogenesis of breast tumors. Our review manuscript provides a comprehensive understanding of key factors regulating DNMT isoforms in breast tumor pathology and documents unsolved issues.

Entities:  

Keywords:  Breast cancer; DNA methylation; DNA methyltransferases; Epigenetics

Mesh:

Substances:

Year:  2021        PMID: 33604794      PMCID: PMC7954751          DOI: 10.1007/s00432-021-03519-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  279 in total

1.  Phosphorylation of HuR by Chk2 regulates SIRT1 expression.

Authors:  Kotb Abdelmohsen; Rudolf Pullmann; Ashish Lal; Hyeon Ho Kim; Stefanie Galban; Xiaoling Yang; Justin D Blethrow; Mark Walker; Jonathan Shubert; David A Gillespie; Henry Furneaux; Myriam Gorospe
Journal:  Mol Cell       Date:  2007-02-23       Impact factor: 17.970

Review 2.  Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence.

Authors:  Kotb Abdelmohsen; Yuki Kuwano; Hyeon Ho Kim; Myriam Gorospe
Journal:  Biol Chem       Date:  2008-03       Impact factor: 3.915

Review 3.  Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation.

Authors:  Olivia S Anderson; Karilyn E Sant; Dana C Dolinoy
Journal:  J Nutr Biochem       Date:  2012-06-27       Impact factor: 6.048

4.  Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.

Authors:  J Adams; P J Carder; S Downey; M A Forbes; K MacLennan; V Allgar; S Kaufman; S Hallam; R Bicknell; J J Walker; F Cairnduff; P J Selby; T J Perren; M Lansdown; R E Banks
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

5.  Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer.

Authors:  Agoston T Agoston; Pedram Argani; Srinivasan Yegnasubramanian; Angelo M De Marzo; Mohammad Ali Ansari-Lari; Jessica L Hicks; Nancy E Davidson; William G Nelson
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

6.  Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.

Authors:  Rita Arabsolghar; Tayebeh Azimi; Mozhgan Rasti
Journal:  Mol Biol Rep       Date:  2012-12-15       Impact factor: 2.316

7.  Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.

Authors:  J C Allegra; M E Lippman; E B Thompson; R Simon; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  Cancer Treat Rep       Date:  1978-09

8.  Flattened cortisol rhythms in metastatic breast cancer patients.

Authors:  Heather C Abercrombie; Janine Giese-Davis; Sandra Sephton; Elissa S Epel; Julie M Turner-Cobb; David Spiegel
Journal:  Psychoneuroendocrinology       Date:  2004-09       Impact factor: 4.905

Review 9.  The possible involvement of virus in breast cancer.

Authors:  Marla Karine Amarante; Maria Angelica Ehara Watanabe
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-14       Impact factor: 4.553

10.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

Authors:  Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Jillian Temple; Andy G Lynch; Mohamed Riad; Raghwa Sharma; Colin Stewart; Sian Fereday; Carlos Caldas; Anna Defazio; David Bowtell; James D Brenton
Journal:  J Pathol       Date:  2010-05       Impact factor: 7.996

View more
  7 in total

Review 1.  Molecular epigenetic dynamics in breast carcinogenesis.

Authors:  Aadrita Hazra; Pritha Bose; Priyashree Sunita; Shakti P Pattanayak
Journal:  Arch Pharm Res       Date:  2021-08-15       Impact factor: 4.946

Review 2.  Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms.

Authors:  Jiaojiao Li; Chunxiao Sun; Wenwen Cai; Jing Li; Barry P Rosen; Jian Chen
Journal:  Mutat Res Rev Mutat Res       Date:  2021-10-07       Impact factor: 7.015

Review 3.  DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy.

Authors:  Xiaxia Man; Qi Li; Baogang Wang; He Zhang; Songling Zhang; Ziyi Li
Journal:  Front Cell Dev Biol       Date:  2022-05-10

Review 4.  Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer.

Authors:  Nguyen Xuan Thang; Seonho Yoo; Hyeonwoo La; Hyeonji Lee; Chanhyeok Park; Kyoung Sik Park; Kwonho Hong
Journal:  Biomedicines       Date:  2022-03-23

5.  27-Hydroxycholesterol, The Estrogen Receptor Modulator, Alters DNA Methylation in Breast Cancer.

Authors:  Ravindran Vini; Arumugam Rajavelu; Sreeja Sreeharshan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-10       Impact factor: 5.555

6.  Downregulation of MEG3 and upregulation of EZH2 cooperatively promote neuroblastoma progression.

Authors:  Mujie Ye; Runnan Gao; Shiyu Chen; Meng Wei; Jing Wang; Bowen Zhang; Suwen Wu; Yuexin Xu; Peixuan Wu; Xin Chen; Jing Ma; Duan Ma; Kuiran Dong
Journal:  J Cell Mol Med       Date:  2022-03-08       Impact factor: 5.310

7.  Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition.

Authors:  Vikas Sharma; Jayadev Joshi; I-Ju Yeh; YongQiu Doughman; Daniel Blankenberg; David Wald; Monica M Montano
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.